Search tips
Search criteria 


Logo of cdiJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
Clin Dev Immunol. 2012; 2012: 284104.
Published online 2012 May 14. doi:  10.1155/2012/284104
PMCID: PMC3359786

Herpes Simplex Virus-2 Glycoprotein Interaction with HVEM Influences Virus-Specific Recall Cellular Responses at the Mucosa


Infection of susceptible cells by herpes simplex virus (HSV) requires the interaction of the HSV gD glycoprotein with one of two principal entry receptors, herpes virus entry mediator (HVEM) or nectins. HVEM naturally functions in immune signaling, and the gD-HVEM interaction alters innate signaling early after mucosal infection. We investigated whether the gD-HVEM interaction during priming changes lymphocyte recall responses in the murine intravaginal model. Mice were primed with attenuated HSV-2 expressing wild-type gD or mutant gD unable to engage HVEM and challenged 32 days later with virulent HSV-2 expressing wild-type gD. HSV-specific CD8+ T cells were decreased at the genital mucosa during the recall response after priming with virus unable to engage HVEM but did not differ in draining lymph nodes. CD4+ T cells, which are critical for entry of HSV-specific CD8+ T cells into mucosa in acute infection, did not differ between the two groups in either tissue. An inverse association between Foxp3+ CD4+ regulatory T cells and CD8+ infiltration into the mucosa was not statistically significant. CXCR3 surface expression was not significantly different among different lymphocyte subsets. We conclude that engagement of HVEM during the acute phase of HSV infection influences the antiviral CD8+ recall response by an unexplained mechanism.

1. Introduction

Herpes simplex virus type 2 (HSV-2) is a common cause of infection, with 17% of American adults seropositive [1]. HSV-2 is most commonly associated with genital infection, and spread of the virus within the population generally results from reactivation of latent infection and subsequent viral shedding [2].

Infection of susceptible human and mouse cells by HSV requires binding of the viral glycoprotein gD with one of its cell surface receptors [3, 4]. HSV gD binds to three general classes of surface receptors, including herpesvirus entry mediator (HVEM), nectin-1 and -2, and specific sites in heparan sulfate [3]. Of these, HVEM and nectin-1 appear to mediate viral entry most efficiently in both humans and mice [5, 6]. The, mouse receptors are orthologous to the human receptors and HSV disease in mice resembles that in humans, allowing application of mouse models to the study of HSV pathogenesis in humans.

HVEM is a member of the tumor necrosis factor (TNF) receptor superfamily of proteins [7]. HVEM is expressed in many tissues, but its principal natural function appears to be in regulating immune responses through interactions with the activating ligand LIGHT or the attenuating binding partners B and T lymphocyte attenuator (BTLA) or CD160 [8]. Although lymphocytes are not thought to be significant targets of HSV infection, since these natural HVEM ligands can either enhance or inhibit lymphocyte activation, it has been suggested that the gD-HVEM interaction could influence lymphocyte-mediated immunity to HSV. The immunologic effects of gD binding to HVEM during HSV infection have not been elucidated in detail, and although our prior work in a murine intravaginal challenge model identified differences in chemokine responses at the mucosa depending on whether virus could engage HVEM, acute cellular responses were not appreciably affected [9].

The possibility that engagement of HVEM by gD can influence memory cellular immune responses to HSV is raised by recent studies of candidate DNA vaccines encoding fusion proteins consisting of viral antigens combined with HSV gD. The results showed that protective antigen-specific CD8+ T-cell responses were enhanced by the presence of gD sequences, providing the domain required for binding to HVEM was functional [1012].

Although most immune cells express HVEM, in the current study we focused on lymphocytes, including regulatory T cells (Tregs). Expression levels of HVEM on immune cells vary at different times in the immune response. Naïve and some memory CD4+ and CD8+ lymphocytes constitutively express HVEM, but expression is downregulated after activation [13, 14]. In mice, lack of HVEM or BTLA expression leads to an increased population of circulating CD8+ T cells with an activated memory phenotype [14]. Optimal activation of dendritic cells (DCs) by CD4+ memory T cells is dependent on the expression of LIGHT [15]. B cell responses may also be potentiated by HVEM/LIGHT interactions [16]. In contrast to effector lymphocytes, Tregs increase HVEM expression after activation [17]. Optimal effector responses of Tregs require both HVEM and BTLA [17]. Intriguingly, HVEM is not expressed on T cells of mice that lack Foxp3 [17], a transcription factor which defines the major Treg subset [18]. Together, these observations suggest an important role for HVEM in the generation and function of effector memory lymphocytes and in the function of Tregs.

In this study, we apply a murine intravaginal model of HSV-2 infection to investigate a role for engagement of HVEM in influencing recall immune responses. We observe differences in the HSV-specific CD8+ T-cell recall response at the genital mucosa based on the gD-HVEM interaction during priming. Differences in replication of the priming virus at the mucosa do not explain the observed differences in CD8+ T-cell infiltration, and neither CD4+ T cell frequency nor CXCR3 expression on responding cells differ for the two conditions. Although we observed a trend suggesting an inverse association with CD4+ Foxp3+ Tregs, we are unable to clearly implicate these cells as contributing to the different CD8+ T-cell recall responses we observed. We conclude that the interaction of gD and HVEM during acute infection with HSV may influence the magnitude and quality of the subsequent recall response at the genital mucosa, though the mechanism remains to be elucidated.

2. Materials and Methods

2.1. Animal Experimentation Guidelines

Animal care and use in this study were in accordance with institutional and NIH guidelines.

2.2. Cells and Viruses

Vero cells were cultured in Dulbecco's modification of Eagle's (DME) medium plus 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin and were used for the propagation and titering of virus. Plaque titrations were performed by standard methods.

HSV-2 strain 333 was originally isolated from a genital lesion and underwent limited passage in human cells [19]. The virus was plaque-purified and passaged no more than three times in Vero cells. Modifications to the glycoprotein gD of HSV-2(333) were previously described [9]. The virulent strain HSV-2(333)/gD used for this study contains wild-type gD flanked by FRT recombination sites. Attenuated versions of HSV-2(333) were created by insertion of a lacZ expression cassette (which results in expression of β-galactosidase) in the UL3-4 intergenic region, as described previously for wild-type HSV-2(333) [20]. Two versions of attenuated virus were used: one contains the wild-type gD flanked by FRT sites (designated HSV-2(333)/gD-βgal) and the second contains a mutant form of gD lacking amino acids 7-15, rendering it unable to engage HVEM (designated HSV-2(333)/Δ7-15-βgal). Prior studies (unpublished) established that these viruses could infect mice but did not lead to mortality or significant clinical symptoms compared to infection with wild-type viruses at the inocula used. The Δ7-15 mutation introduced into the gD gene had only minor effects on mucosal replication relative to virus with wild-type gD in our prior studies [9].

2.3. Animal Procedures

Female C57BL/6 mice between 6–10 weeks of age were purchased from Jackson Labs and maintained in specific-pathogen-free conditions until inoculation. Mice were transferred to a containment facility for inoculation, which occurred before 12 weeks of age. Susceptibility of mice to intravaginal infection was ensured by subcutaneous injection 6 days prior to inoculation with 2.5 mg of medroxyprogesterone acetate (Depo-Provera, Pharmacia) in phosphate-buffered saline (PBS) [21]. At the time of inoculation, mice were anesthetized with ketamine-xylazine, vaginas were swabbed to clear secretions, and virus was delivered intravaginally via micropipette in 20 mL total volume. Virus was diluted in PBS containing 1% inactivated calf serum and 0.1% glucose to deliver 6 × 105 PFU/mouse. All mice first received inoculation with attenuated viruses (“priming”) and were challenged with virulent HSV-2(333)/gD 32 days after priming (“challenge”). Mice were sacrificed 3 days after challenge for evaluation of cellular immune responses. Clinical symptoms were generally not observed after either inoculation, though sporadically individual mice primed with attenuated viruses had perivaginal hair loss or mild lesions which resolved prior to challenge.

2.4. Measurement of Viral Replication in the Vaginal Tract

To assess replication of the attenuated virus in the vaginal tract, secretions were collected from infected mice at indicated times. Sterile PBS was instilled intravaginally in a 40 μL volume and pipetted in and out 2-3 times (see e.g., [22]). This was repeated twice and samples pooled for analysis by standard plaque assay. Samples were stored at −70°C until analysis.

2.5. Isolation of Lymphocytes

Lymphocytes were isolated from draining lymph nodes (DLN) and vaginal tissue. DLNs from each mouse were separately homogenized in RPMI-1640 with 2% heat-inactivated FBS. Red blood cells were lysed with ACK buffer, and cells were washed, counted, and maintained in complete medium (RPMI-1640, 10% FBS, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 1% penicillin-streptomycin, and 20 mM β-mercaptoethanol) prior to labeling for flow cytometric evaluation.

Vaginal tissue was processed by a similar protocol we previously used [9], based on method described by Gierynska et al. [23]. Briefly, isolated tissue was washed in Hanks balanced salt solution (HBSS), cut into small pieces, and incubated in HBSS with collagenase D (1 mg/mL) for 1 hour at 37°C with gentle agitation. Digested tissue was pressed through a cell strainer, washed in RPMI-1640 with 2% heat-inactivated FBS, and the cells counted and resuspended in complete medium. There were no differences between the groups in the overall numbers of cells recovered from any tissue.

2.6. Measurement of Murine T-Cell Responses by Flow Cytometry

Isolated cells were washed and resuspended in FACS buffer. Surface labeling included fluorescently conjugated antibodies to murine CD4, CD8, CXCR3, and DimerX-PE reagent (BD Biosciences) preloaded with the gB496–503 peptide according to the manufacturer's instructions. A cell permeabilization kit was used for intracellular labeling with fluorescently conjugated antibody to murine Foxp3 (BD Biosciences). Cells were analyzed using an LSR II flow cytometer (Becton-Dickinson) and FloJo software (TreeStar). Lymphocytes were gated based on forward and side-scatter characteristics, with isotype control antibodies used to determine the threshold for positive labeling with Foxp3 and CXCR3. Lymphocytes from uninfected mice were used for negative control labeling with the DimerX reagent. A minimum of 10000 events were collected for each condition analyzed. Percentages in different subsets were measured based on fluorescence detected at relevant wavelengths.

2.7. Statistical Tests

Mean percentages of fluorescently labeled cells within a population were compared between experimental groups using the unpaired Student's t-test.

3. Results

3.1. Replication of the Virus within the Murine Vaginal Tract Is Only Minimally Affected by the Ability of the Virus to Interact with HVEM

Our prior studies had noted only minor differences in viral replication in the vaginal tract after infection with the virulent strains HSV-2(333)/gD and HSV-2(333)/Δ7-15 [9]. To confirm that the attenuated strains of these viruses (HSV-2(333)/gD-βgal and HSV-2(333)/Δ7-15-βgal, resp.) also had similar replication kinetics in the vaginal tract, we inoculated groups of mice with the two attenuated viruses and measured viral titers in vaginal secretions over time (Figure 1). The strain of virus unable to engage HVEM was about 0.5 log lower in titer on day 1 (P = 0.05), but there were no statistical differences in titer on subsequent days. We conclude that the Δ7-15 deletion in gD, which abrogates the ability of the virus to use HVEM as an entry receptor without altering its ability to use nectin-1, does not greatly alter in vivo replication of the attenuated virus strains.

Figure 1
HSV-2 titers in the vaginal tract after infection with the attenuated viruses HSV-2(333)/gD-βgal or HSV-2(333)/Δ7-15-βgal are only minimally affected by engagement of HVEM. Viral titers were measured in vaginal secretions on the ...

3.2. HSV-Specific CD8+ T-Cell Mucosal Recall Responses Are Diminished by HSV-2 Interaction with HVEM during Priming

Female mice were primed with either HSV-2(333)/gD-βgal or HSV-2(333)/Δ7-15-βgal and challenged with HSV-2(333)/gD (Figure 2(a)). Studies of the CD8+ T-cell immune response after HSV infection of C57BL/6 mice have identified an immunodominant H-2Kb-restricted epitope in the gB glycoprotein (gB496–503), which accounts for >70% of the CD8+ cellular immune response [24, 25], allowing measurement of HSV-specific responses using fluorescently labeled MHC dimers loaded with the dominant peptide [26]. HSV-specific CD8+ lymphocytes were present at a significantly greater frequency in vaginal mucosa three days after challenge with HSV-2(333)/gD in animals which were previously primed with HSV-2(333)/gD-βgal, compared to those primed with HSV-2(333)/Δ7-15-βgal (Figures 2(b) and and3).3).

Figure 2
(a) Schematic of experimental design. (b) The HSV-specific CD8+ T cell response at the vaginal mucosa in individual mice differs in the recall phase depending on whether HVEM was engaged during priming. Representative examples from individual mice within ...
Figure 3
HSV-specific CD8+ T cell frequencies do not differ in lymphocytes isolated from (a) draining lymph nodes from groups of mice primed with viruses than can (HSV-2/gD-βgal, left, open circles) or cannot (HSV-2/gD-Δ7-15-βgal, right, ...

Priming with virus able to engage HVEM led to more than twofold increase in the mean percentage of HSV-specific CD8+ T cells recovered at the vaginal mucosa compared to priming with virus unable to engage HVEM. No differences were seen in the frequency of HSV-specific CD8+ lymphocytes isolated from DLN (Figures 2(b) and and3).3). There were also no differences found in the mean percentage of CD8+ T cells (independent of gB496–503 antigen specificity) isolated from vaginal mucosa or DLN between the two groups (data not shown). We conclude that the interaction of HSV gD with HVEM during initial infection of C57BL/6 mice results in an increased frequency of HSV-specific CD8+ T cells at the mucosa but not the DLN during the recall response after challenge with virulent HSV-2 expressing wild-type gD.

3.3. Engagement of HVEM during Priming Does Not Alter CD4+ T-Cell Frequencies in the DLN or Vaginal Mucosa during the Recall Response

Prior investigators have demonstrated a crucial role for CD4+ T cells to direct entry of virus-specific CD8+ T cells into mucosal tissue after acute HSV infection via secretion of interferon-γ (IFN-γ) and induction of chemokine production [27]. Our previous study detected no differences in the frequencies of IFN-γ producing CD4+ T cells after acute infection using viruses that were or were not able to engage HVEM [9]. Since differences in the frequencies of CD4+ T cells (and by inference the amount of IFN-γ produced) in the vaginal tissue during the recall response could explain differences in the frequencies of infiltrating virus-specific CD8+ T cells, we measured CD4+ T-cell infiltration into mucosal tissue and DLN during the recall response (Figure 4). In contrast to the results for HSV-specific CD8+ T cells, no differences in the frequencies of infiltrating CD4+ T cells were seen in the vaginal mucosa or DLN of mice primed with HSV-2(333)/Δ7-15-βgal compared to those primed with HSV-2(333)/gD-βgal. We conclude that the initial interaction of HSV with gD during the priming phase of the immune response in C57BL/6 mice does not alter the CD4+ T-cell response in DLN or vaginal mucosa during the challenge phase. However, our data cannot rule out differences in IFN-γ production by responding CD4+ T cells in the recall response.

Figure 4
CD4+ T cell frequencies do not differ in draining lymph nodes (a) or vaginal mucosa (b) among lymphocytes isolated from groups of mice primed with viruses that can (HSV-2/gD-βgal, left, open circles) or cannot (HSV-2/gD-Δ7-15-β ...

3.4. Regulatory T-Cell Infiltration into Infected Tissue during the Recall Response May Be Altered by Prior Engagement of HVEM

Tregs have an important role in directing the acute cellular immune response to mucosal HSV infection in mice by altering the chemokine and cytokine gradient between the infected tissue and draining lymph nodes [28]. Since alterations in Treg frequencies in different tissues during the recall response could lead to the differences we observed in antiviral CD8+ T cell frequencies, we assessed Treg frequency during the recall response in our infection model. Foxp3+ CD4+ Tregs were detected at a lower frequency in vaginal mucosa of mice primed with HSV-2(333)/Δ7-15-βgal compared to mice primed with HSV-2(333)/gD-βgal (Figure 5); however, this difference did not reach statistical significance. No differences were detected in Foxp3+CD4+ Tregs in DLN between the different experimental groups. Although the trend observed for Treg infiltration into vaginal mucosa during the recall response was inversely related to the infiltration of HSV-specific CD8+ T cells, due to the lack of statistical significance we are unable to firmly implicate a role for Tregs in directing this response.

Figure 5
Foxp3+CD4+T cell frequencies do not significantly differ in draining lymph nodes (a) or vaginal mucosa (b) among lymphocytes isolated from groups of mice primed with viruses that can (HSV-2/gD-βgal, left, open circles) or cannot (HSV-2/gD-Δ7-15- ...

3.5. Homing Receptor Expression on HSV-Specific T Cells during the Recall Response Is Not Affected by Prior Engagement of HVEM

Recruitment of effector T cells to infected mucosal tissue is dependent on expression of CXCR3 [27], which is the receptor for the chemokines CXCL9 and CXCL10. We previously observed that levels of both CXCL9 and CXCL10 were affected in the acute phase of HSV infection based on whether the virus could engage HVEM [9]. CXCR3 is important in priming T cell responses and has a potential role in inducing T cell memory [29], and a possible explanation for the differences in CD8+ T cell infiltration we observed could be related to expression of this homing receptor. Accordingly, we assayed the expression of CXCR3 on different subsets of lymphocytes in draining lymph nodes and vaginal tissue during the recall response. Mean fluorescence intensity of CXCR3 expression on CD8+, CD4+, and Foxp3+CD4+T cells did not differ based on whether the priming virus was able to engage HVEM (Figure 6). We conclude that despite our prior observation of differences in chemokine production based on HVEM expression in the acute response [9], no measurable differences in chemokine receptor expression may be demonstrated during the recall response on the basis of gD interactions with HVEM during priming.

Figure 6
CXCR3 expression on CD8+, CD4+, and Foxp3+ CD4+ T cells does not statistically differ between groups of mice primed with viruses that can (HSV-2/gD-βgal, black bars) or cannot (HSV-2/gD-Δ7-15-βgal, stippled bars) engage HVEM. Gates ...

4. Discussion

Our study describes a role for the acute interaction of HSV-2 gD with HVEM in modifying the antiviral recall immune response after intravaginal infection of mice. Our principal observation was that engagement of HVEM during acute infection (priming) increased the HSV-specific CD8+ T-cell response at the mucosa during rechallenge. We investigated several possible contributing factors for this observation, but were unable to clearly demonstrate roles for CD4+ T-cells, Foxp3+CD4+ Tregs, or expression of the chemokine receptor CXCR3 on responding cells in relation to whether the priming virus was able to engage HVEM.

We used the well-established murine intravaginal challenge model for these studies [21] to investigate the antiviral cellular recall response at the mucosa. This model is limited for studying HSV-2 pathogenesis in mice by mortality in productively infected animals when wild-type virus is used, requiring us to generate initial antiviral immune responses by priming with an attenuated virus. Mice can be protected against disease after intravaginal challenge with wild-type virus by a variety of means, including passive antibody transfer [30] and by generation of HSV-specific cellular responses [23, 31, 32], and from preliminary studies we knew that our attenuated viruses could provide protection against subsequent wild-type HSV challenge. We did not formally demonstrate the mechanism for this protection, but we expect that priming with either virus leads to both humoral and cellular immunity capable of mediating protection. Since our prior work [9] and current data (Figure 1) also demonstrate that mutation of gD to abrogate interaction with HVEM has only minor effects on local viral replication in the intravaginal model, we believe our results reflect an effect that is primarily attributable to the relative ability of the priming viruses to engage HVEM. Memory T cell responses are generated from a minor population within the effector pool of CD8+ T cells [33], and antiviral T cell activation and expansion are barely underway 24 hours after infection [34]. Also, the numbers of memory T cells generated following resolution of an acute infection are thought to depend at least in part on the peak response during the effector phase of the cellular immune response [34]; our prior data did not identify differences in the peak HSV-specific CD8+ T cell response on the basis of viral engagement of HVEM [9]. Therefore, the small replication difference between the two viruses one day after inoculation (0.5 log PFU/mL) would be unlikely to explain the more than twofold difference in recall response at the mucosa.

A second potential alternative explanation for our findings is that the gB-specific recall response is specifically altered by engagement of HVEM during priming, leading to a recall response that is perhaps HSV-specific but involves subdominant epitopes. Consistent with this possibility is our observation that overall CD8+ T cell frequencies in mucosal tissue were unaltered in the recall response. However, our prior findings of no differences in the acute CD8+ T cell response to gB496–503 after challenge with virulent HSV-2(333)/gD compared to HSV-2(333)/Δ7-15, combined with the understanding that memory responses are partly dependent on peak responses [34], suggest against this possibility. Nevertheless, we are unable to completely rule out this alternative explanation with our data.

HVEM is a member of the TNF receptor family, which is broadly expressed in hematopoietic cells [35, 36]. Signaling through HVEM results in different responses in immune cells depending on the context in which it is engaged [8]. Engagement of HVEM by LIGHT or lymphotoxin-α increases T-cell activation [35], while BTLA [37, 38] and CD160 [39] attenuate T-cell activation and proliferation upon interaction with HVEM. Although lymphocytes are not generally considered to be targets of infection with HSV in vivo, the interaction of HSV gD on the viral envelope and on infected cells may modulate lymphocyte activity through an interaction with HVEM. HSV gD binds to HVEM in the same membrane-distal cysteine-rich domain (CRD1) [40] as both BTLA [41] and CD160 [39], and soluble gD competitively inhibits the BTLA-HVEM interaction [38]. The interaction of gD with HVEM can itself trigger NF-κB activation [42]. Also, gD might competitively inhibit the binding of HVEM to BTLA or CD160, with consequences that depend on the effects of the HVEM-BTLA/CD160 interactions. The HSV gD interactions with HVEM may also alter responses of other (nonlymphocyte) immune cells which express HVEM or its ligands, such as dendritic cells, whose homeostasis is dependent on HVEM and BTLA signaling [43], and NK cells, which may be activated by engagement of CD160 [44].

Given the multiple combinations for binding between HVEM and its multiple ligands, between LIGHT and its binding partners HVEM and the lymphotoxin-β receptor (LT-βR), and the differential regulation of expression of these molecules on different cell types during an inflammatory response, a mechanism by which any of the above interactions would be altered by gD to affect memory T-cell responses is not immediately obvious. Prior studies in BTLA-deficient mice show increased differentiation of naïve CD8+ T cells into central memory cells in the absence of BTLA [14], suggesting that our results could be explained by interference of HVEM-BTLA signaling by gD during acute infection. Optimal Treg responses are also dependent on the HVEM-BTLA signaling pathway [17]; upregulation of HVEM by Tregs and BTLA by effector T cells after TCR stimulation suggests the hypothesis that the level of Treg signaling to effector T cells through HVEM-BTLA during the acute response may program subsequent memory cell differentiation, controlling either the numbers or other characteristics of the memory cell population (e.g., migratory characteristics might be altered by effects on chemokine receptor expression). However, as other cell types also express HVEM and BTLA, including DCs and NK cells, a role for HVEM signaling by these cells in the shaping of the memory immune response is also possible.

Several lines of evidence suggest possible ways that the chemokine and cytokine environment within which the acute immune response is developing may influence the generation and persistence of memory cells. Antigen-specific CD4+ T cells have recently been shown to require expression of both LIGHT and HVEM to persist as memory cells [45]. Expression of the chemokine receptor CXCR3 on T cells in DLNs has also been implicated in induction of T-cell memory [29]. Any modulation of HVEM-LIGHT signaling by gD could affect either or both of these pathways. It is also possible that memory cell generation and persistence is not affected by the initial gD-HVEM interaction, but subsequent chemokine production or chemokine receptor expression by memory cells is programmed in some manner by the initial context of HVEM signaling, leading to changes in chemokine gradients during the recall response, which change the relative infiltration of different memory lymphocytes. We did not measure the chemokine response in the challenge phase in these experiments, and CXCR3 measurements did not reveal a role for expression of this receptor in the response we observed. Further work on defining the underlying mechanism for our observations is ongoing, including evaluation of different time points and experiments using adoptive transfer and HVEM knockout mice.

To our knowledge, this study is the first to show an influence of the HSV gD-HVEM interaction on recall immune responses in an HSV infection model. However, an influence of the gD-HVEM interaction on memory immunity is not entirely unexpected based on prior vaccine studies [1012]. In these investigations, candidate vaccines were constructed to express different viral antigens fused to the C-terminal domain of HSV-1 gD and delivered intramuscularly to mice. These constructs induced stronger immune responses than those which lacked either the gD fusion or in which gD was unable to interact with HVEM. The authors attributed this observation primarily to interference by gD with coinhibitory signaling by the natural BTLA-HVEM interaction.

Among the many questions left unanswered by our work is whether any advantage is conferred to the virus by manipulation of HVEM signaling pathways. It seems counterintuitive that HSV evolved to use a receptor that ultimately leads to a stronger recall response at the site of initial infection than if a different entry receptor had been used. One possibility is that initial establishment of infection is favored by the use of gD to disrupt HVEM signaling [9]. If virus is able to reactivate and shed even in the presence of a strong recall response, it is possible that there is no significant selection pressure against this effect. Further investigation into the pleiotropic functions of HVEM in immunity may shed light on this question.

Finally, it is worth commenting further on the implications of this observation on pathogenesis of HSV disease and possible therapeutics, including vaccination. Studies of human trigeminal ganglia and skin biopsy samples strongly support the concept that memory CD8+ T-cell responses are critical for the control of recurrent infection [46, 47]. Manipulation of HVEM signaling to properly direct these responses to relevant tissues could benefit therapeutic vaccine strategies [11]. There may also be implications for disease recurrence. Although a prior study of individuals with HSV-specific cellular immunity but no serologic or clinical evidence of infection failed to identify HVEM polymorphisms which altered viral entry into cells [48], it is possible that HVEM variants may lead to signaling differences that either promote or diminish effective mucosal cellular immune responses during viral reactivation. A similar survey of HVEM variants in patients with frequent recurrences has not been completed.

5. Conclusions

We have described a role for the initial interaction of HSV gD with HVEM in shaping the antiviral CD8+ T cell recall response at the mucosa. Further studies are needed to elucidate the mechanism behind this effect, and how it may contribute to HSV pathogenesis and perhaps influence the design of therapeutic interventions, including vaccines.


This paper was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (Grant no. 5K08 AI089942 to W. J. Muller) and by an Infectious Diseases Society of America Education and Research Foundation/National Foundation for Infectious Diseases Young Investigator Award (to W. J. Muller). The authors also wish to thank Nanette Susmarski for providing cell culture expertise and assistance in viral preparation and titering. They also appreciate many helpful comments and guidance from Patricia Spear, Richard Longnecker, Gregory Smith, Anne Rowley, Steve Miller, John Bechill, Andrew Karaba, and other members of the Longnecker and Miller Laboratories. This work received assistance from the Northwestern University Interdepartmental Immunobiology Flow Cytometry Core Facility.


1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. Journal of the American Medical Association. 2006;296(8):964–973. [PubMed]
2. Sacks S, Griffiths PD, Corey L, et al. HSV shedding. Antiviral Research. 2004;63(supplement 1):S19–S26. [PubMed]
3. Spear PG, Eisenberg RJ, Cohen GH. Three classes of cell surface receptors for alphaherpesvirus entry. Virology. 2000;275(1):1–8. [PubMed]
4. Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cellular Microbiology. 2004;6(5):401–410. [PubMed]
5. Lopez M, Cocchi F, Menotti L, Avitabile E, Dubreuil P, Campadelli-Fiume G. Nectin2α (PRR2α or HveB) and nectin2δ are low-efficiency mediators for entry of herpes simplex virus mutants carrying the Leu25Pro substitution in glycoprotein D. Journal of Virology. 2000;74(3):1267–1274. [PMC free article] [PubMed]
6. Shukla D, Liu J, Blaiklock P, et al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell. 1999;99(1):13–22. [PubMed]
7. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell. 1996;87(3):427–436. [PubMed]
8. Šedý J, Spear P, Ware C. Cross-regulation between herpesviruses and the TNF superfamily members. Nature Reviews Immunology. 2008;8(11):861–873. [PMC free article] [PubMed]
9. Yoon M, Kopp SJ, Taylor JM, Storti CS, Spear PG, Muller WJ. Functional interaction between herpes simplex virus type 2 gD and HVEM transiently dampens local chemokine production after murine mucosal infection. Plos ONE. 2011;6(1) Article ID e16122. [PMC free article] [PubMed]
10. Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes and Infection. 2005;7(15):1541–1550. [PubMed]
11. Lasaro MO, Tatsis N, Hensley SE, et al. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nature Medicine. 2008;14(2):205–212. [PMC free article] [PubMed]
12. DiMenna L, Latimer B, Parzych E, et al. Augmentation of primary influenza A virus-specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway. Journal of Immunology. 2010;184(10):5475–5484. [PubMed]
13. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nature Reviews Immunology. 2003;3(8):609–620. [PubMed]
14. Krieg C, Boyman O, Fu YX, Kaye J. B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nature Immunology. 2007;8(2):162–171. [PubMed]
15. Morel Y, Truneh A, Costello RT, Olive D. LIGHT, a new TNF superfamily member, is essential for memory T helper cell-mediated activation of dendritic cells. European Journal of Immunology. 2003;33(11):3213–3219. [PubMed]
16. Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello RT. LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T cell-dependent B cell terminal differentiation. European Journal of Immunology. 2004;34(12):3534–3541. [PubMed]
17. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. Journal of Immunology. 2008;180(10):6649–6655. [PubMed]
18. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunology. 2005;6(4):345–352. [PubMed]
19. Westmoreland D, Rapp F. Host range temperature sensitive mutants of herpes simplex virus type 2. Journal of Virology. 1976;18(1):92–102. [PMC free article] [PubMed]
20. Taylor JM, Lin E, Susmarski N, et al. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host and Microbe. 2007;2(1):19–28. [PMC free article] [PubMed]
21. Parr M, Kepple L, McDermott M, Drew M, Bozzola J, Parr E. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Laboratory Investigation. 1994;70(3):369–380. [PubMed]
22. Milligan G, Bernstein D. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract. Virology. 1995;206(1):234–241. [PubMed]
23. Gierynska M, Kumaraguru U, Eo SK, Lee S, Krieg A, Rouse BT. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. Journal of Virology. 2002;76(13):6568–6576. [PMC free article] [PubMed]
24. Stock A, Jones C, Heath W, Carbone F. CTL response compensation for the loss of an immunodominant class I-restricted HSV-1 determinant. Immunology and Cell Biology. 2006;84(6):543–550. [PubMed]
25. Wallace M, Keating R, Heath W, Carbone F. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. Journal of Virology. 1999;73(9):7619–7626. [PMC free article] [PubMed]
26. Muller WJ, Orgun NN, Dong L, Koelle DM, Huang ML, Way SS. Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2. Archives of Virology. 2008;153(6):1165–1169. [PMC free article] [PubMed]
27. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature. 2009;462(7272):510–513. [PMC free article] [PubMed]
28. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science. 2008;320(5880):1220–1224. [PMC free article] [PubMed]
29. Groom JR, Luster AD. CXCR3 in T cell function. Experimental Cell Research. 2011;317(5):620–631. [PMC free article] [PubMed]
30. Parr E, Parr M. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. Journal of Virology. 1997;71(11):8109–8115. [PMC free article] [PubMed]
31. Blaney JE, Jr., Nobusawa E, Brehm MA, et al. Immunization with a single major histocompatibility complex class I- restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. Journal of Virology. 1998;72(12):9567–9574. [PMC free article] [PubMed]
32. Kumaraguru U, Gierynska M, Norman S, Bruce BD, Rouse BT. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. Journal of Virology. 2002;76(1):136–141. [PMC free article] [PubMed]
33. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. Journal of Virology. 2004;78(11):5535–5545. [PMC free article] [PubMed]
34. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nature Reviews Immunology. 2002;2(4):251–262. [PubMed]
35. Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity. 1998;8(1):21–30. [PubMed]
36. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. Journal of Biological Chemistry. 1997;272(22):14029–14032. [PubMed]
37. Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nature Immunology. 2005;6(1):90–98. [PubMed]
38. Gonzalez LC, Loyet KM, Calemine-Fenaux J, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(4):1116–1121. [PubMed]
39. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nature Immunology. 2008;9(2):176–185. [PubMed]
40. Carfí A, Willis S, Whitbeck J, et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Molecular Cell. 2001;8(1):169–179. [PubMed]
41. Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. Journal of Biological Chemistry. 2005;280(47):39553–39561. [PubMed]
42. Cheung TC, Steinberg MW, Oborne LM, et al. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(15):6244–6249. [PubMed]
43. De Trez C, Schneider K, Potter K, et al. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin β receptor signaling to achieve homeostasis of dendritic cells. Journal of Immunology. 2008;180(1):238–248. [PMC free article] [PubMed]
44. Barakonyi A, Rabot M, Marie-Cardine A, et al. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. Journal of Immunology. 2004;173(9):5349–5354. [PubMed]
45. Soroosh P, Doherty TA, So T, et al. Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations. Journal of Experimental Medicine. 2011;208(4):797–809. [PMC free article] [PubMed]
46. Verjans GM, Hintzen RQ, van Dun JM, et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(9):3496–3501. [PubMed]
47. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. Journal of Experimental Medicine. 2007;204(3):595–603. [PMC free article] [PubMed]
48. Struyf F, Posavad CM, Keyaerts E, Van Ranst M, Corey L, Spear PG. Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals. Journal of Infectious Diseases. 2002;185(1):36–44. [PubMed]

Articles from Clinical and Developmental Immunology are provided here courtesy of Hindawi